Company Description
Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally.
The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets.
The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer.
It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.
The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020.
Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
| Country | United States |
| Founded | 2015 |
| IPO Date | Nov 20, 2020 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 3,000 |
| CEO | Michael Petras |
Contact Details
Address: 9100 South Hills Blvd, Suite 300 Broadview Heights, Ohio 44147 United States | |
| Phone | 440 262 1410 |
| Website | soterahealth.com |
Stock Details
| Ticker Symbol | SHC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001822479 |
| CUSIP Number | 83601L102 |
| ISIN Number | US83601L1026 |
| Employer ID | 47-3531161 |
| SIC Code | 8090 |
Key Executives
| Name | Position |
|---|---|
| Michael B. Petras Jr. | Chairman and Chief Executive Officer |
| Jonathan M. Lyons | Senior Vice President and Chief Financial Officer |
| Alexander Dimitrief J.D. | Senior Vice President, General Counsel and Secretary |
| Michael P. Rutz | President of Sterigenics |
| Robert G. Hauzie | Chief Information Officer |
| Kristin A. Gibbs | Chief Marketing Officer |
| William O. Lehmann Jr., J.D., M.B.A. | Senior Vice President of Strategy and Corporate Development |
| Sally R. Turner | Chief Human Resources Officer |
| Danielle J. Menture | Senior Vice President of Global Environmental, Health and Safety and Sustainability |
| Joseph A. Shrawder | President of Nelson Labs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2025 | ARS | Filing |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 27, 2025 | 8-K | Current Report |
| Jan 14, 2025 | 8-K | Current Report |
| Jan 6, 2025 | 8-K | Current Report |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |